Associations - Imjudo (tremelimumab)

No biomarker	Non Small Cell Lung Cancer	No biomarker	Non Small Cell Lung Cancer	durvalumab + tremelimumab Sensitive: A1 - Approval durvalumab + tremelimumab Sensitive : A1	durvalumab + tremelimumab Sensitive: A1 - Approval durvalumab + tremelimumab Sensitive : A1
No biomarker	Hepatocellular Cancer	No biomarker	Hepatocellular Cancer	durvalumab + tremelimumab Sensitive: A1 - Approval durvalumab + tremelimumab Sensitive : A1	durvalumab + tremelimumab Sensitive: A1 - Approval durvalumab + tremelimumab Sensitive : A1
PD-L1 expression	Lung Non-Small Cell Squamous Cancer	PD-L1 expression	Lung Non-Small Cell Squamous Cancer	durvalumab + tremelimumab Sensitive: A2 - Guideline durvalumab + tremelimumab Sensitive : A2	durvalumab + tremelimumab Sensitive: A2 - Guideline durvalumab + tremelimumab Sensitive : A2
PD-L1 expression	Lung Non-Squamous Non-Small Cell Cancer	PD-L1 expression	Lung Non-Squamous Non-Small Cell Cancer	durvalumab + tremelimumab Sensitive: A2 - Guideline durvalumab + tremelimumab Sensitive : A2	durvalumab + tremelimumab Sensitive: A2 - Guideline durvalumab + tremelimumab Sensitive : A2
PD-L1 overexpression	Lung Non-Small Cell Squamous Cancer	PD-L1 overexpression	Lung Non-Small Cell Squamous Cancer	durvalumab + tremelimumab Sensitive: A2 - Guideline durvalumab + tremelimumab Sensitive : A2	durvalumab + tremelimumab Sensitive: A2 - Guideline durvalumab + tremelimumab Sensitive : A2
PD-L1 overexpression	Lung Non-Squamous Non-Small Cell Cancer	PD-L1 overexpression	Lung Non-Squamous Non-Small Cell Cancer	durvalumab + tremelimumab Sensitive: A2 - Guideline durvalumab + tremelimumab Sensitive : A2	durvalumab + tremelimumab Sensitive: A2 - Guideline durvalumab + tremelimumab Sensitive : A2
No biomarker	Lung Adenocarcinoma	No biomarker	Lung Adenocarcinoma	durvalumab + tremelimumab Sensitive: A2 - Guideline durvalumab + tremelimumab Sensitive : A2	durvalumab + tremelimumab Sensitive: A2 - Guideline durvalumab + tremelimumab Sensitive : A2
No biomarker	Lung Non-Small Cell Squamous Cancer	No biomarker	Lung Non-Small Cell Squamous Cancer	durvalumab + tremelimumab Sensitive: A2 - Guideline durvalumab + tremelimumab Sensitive : A2	durvalumab + tremelimumab Sensitive: A2 - Guideline durvalumab + tremelimumab Sensitive : A2
MSI-H/dMMR	Gastroesophageal Junction Adenocarcinoma	MSI-H/dMMR	Gastroesophageal Junction Adenocarcinoma	durvalumab + tremelimumab Sensitive: A2 - Guideline durvalumab + tremelimumab Sensitive : A2	durvalumab + tremelimumab Sensitive: A2 - Guideline durvalumab + tremelimumab Sensitive : A2
MSI-H/dMMR	Gastric Cancer	MSI-H/dMMR	Gastric Cancer	durvalumab + tremelimumab Sensitive: A2 - Guideline durvalumab + tremelimumab Sensitive : A2	durvalumab + tremelimumab Sensitive: A2 - Guideline durvalumab + tremelimumab Sensitive : A2
MSI-H/dMMR	Esophageal Cancer	MSI-H/dMMR	Esophageal Cancer	durvalumab + tremelimumab Sensitive: A2 - Guideline durvalumab + tremelimumab Sensitive : A2	durvalumab + tremelimumab Sensitive: A2 - Guideline durvalumab + tremelimumab Sensitive : A2
TMB-H	Urothelial Cancer	TMB-H	Urothelial Cancer	durvalumab + tremelimumab Sensitive: B - Late Trials durvalumab + tremelimumab Sensitive : B	durvalumab + tremelimumab Sensitive: B - Late Trials durvalumab + tremelimumab Sensitive : B
ARID1A mutation	Non Small Cell Lung Cancer	ARID1A mutation	Non Small Cell Lung Cancer	durvalumab + tremelimumab Sensitive: B - Late Trials durvalumab + tremelimumab Sensitive : B	durvalumab + tremelimumab Sensitive: B - Late Trials durvalumab + tremelimumab Sensitive : B
TMB-H	Non Small Cell Lung Cancer	TMB-H	Non Small Cell Lung Cancer	durvalumab + tremelimumab Sensitive: B - Late Trials durvalumab + tremelimumab Sensitive : B	durvalumab + tremelimumab Sensitive: B - Late Trials durvalumab + tremelimumab Sensitive : B
PD-L1 expression	Non Small Cell Lung Cancer	PD-L1 expression	Non Small Cell Lung Cancer	durvalumab + tremelimumab Sensitive: B - Late Trials durvalumab + tremelimumab Sensitive : B	durvalumab + tremelimumab Sensitive: B - Late Trials durvalumab + tremelimumab Sensitive : B
TMB-H	Squamous Cell Carcinoma of Head and Neck	TMB-H	Squamous Cell Carcinoma of Head and Neck	durvalumab + tremelimumab Sensitive: B - Late Trials durvalumab + tremelimumab Sensitive : B	durvalumab + tremelimumab Sensitive: B - Late Trials durvalumab + tremelimumab Sensitive : B
KMT2D mutation	Squamous Cell Carcinoma of Head and Neck	KMT2D mutation	Squamous Cell Carcinoma of Head and Neck	durvalumab + tremelimumab Sensitive: B - Late Trials durvalumab + tremelimumab Sensitive : B	durvalumab + tremelimumab Sensitive: B - Late Trials durvalumab + tremelimumab Sensitive : B
PD-L1 overexpression	Squamous Cell Carcinoma of Head and Neck	PD-L1 overexpression	Squamous Cell Carcinoma of Head and Neck	durvalumab + tremelimumab Sensitive: B - Late Trials durvalumab + tremelimumab Sensitive : B	durvalumab + tremelimumab Sensitive: B - Late Trials durvalumab + tremelimumab Sensitive : B
ATM mutation	Squamous Cell Carcinoma of Head and Neck	ATM mutation	Squamous Cell Carcinoma of Head and Neck	durvalumab + tremelimumab Sensitive: B - Late Trials durvalumab + tremelimumab Sensitive : B	durvalumab + tremelimumab Sensitive: B - Late Trials durvalumab + tremelimumab Sensitive : B
STK11 mutation	Lung Non-Squamous Non-Small Cell Cancer	STK11 mutation	Lung Non-Squamous Non-Small Cell Cancer	durvalumab + tremelimumab Sensitive: B - Late Trials durvalumab + tremelimumab Sensitive : B	durvalumab + tremelimumab Sensitive: B - Late Trials durvalumab + tremelimumab Sensitive : B
PD-L1 underexpression	Non Small Cell Lung Cancer	PD-L1 underexpression	Non Small Cell Lung Cancer	durvalumab + tremelimumab Sensitive: B - Late Trials durvalumab + tremelimumab Sensitive : B	durvalumab + tremelimumab Sensitive: B - Late Trials durvalumab + tremelimumab Sensitive : B
HLA-DQB1*03:01	Small Cell Lung Cancer	HLA-DQB1*03:01	Small Cell Lung Cancer	durvalumab + tremelimumab Sensitive: B - Late Trials durvalumab + tremelimumab Sensitive : B	durvalumab + tremelimumab Sensitive: B - Late Trials durvalumab + tremelimumab Sensitive : B
EGFR wild-type	Non Small Cell Lung Cancer	EGFR wild-type	Non Small Cell Lung Cancer	durvalumab + tremelimumab Sensitive: B - Late Trials durvalumab + tremelimumab Sensitive : B	durvalumab + tremelimumab Sensitive: B - Late Trials durvalumab + tremelimumab Sensitive : B
ALK wild-type	Non Small Cell Lung Cancer	ALK wild-type	Non Small Cell Lung Cancer	durvalumab + tremelimumab Sensitive: B - Late Trials durvalumab + tremelimumab Sensitive : B	durvalumab + tremelimumab Sensitive: B - Late Trials durvalumab + tremelimumab Sensitive : B
KRAS mutation	Non Small Cell Lung Cancer	KRAS mutation	Non Small Cell Lung Cancer	durvalumab + tremelimumab Sensitive: B - Late Trials durvalumab + tremelimumab Sensitive : B	durvalumab + tremelimumab Sensitive: B - Late Trials durvalumab + tremelimumab Sensitive : B
KEAP1 mutation	Non Small Cell Lung Cancer	KEAP1 mutation	Non Small Cell Lung Cancer	durvalumab + tremelimumab Sensitive: B - Late Trials durvalumab + tremelimumab Sensitive : B	durvalumab + tremelimumab Sensitive: B - Late Trials durvalumab + tremelimumab Sensitive : B
STK11 mutation	Non Small Cell Lung Cancer	STK11 mutation	Non Small Cell Lung Cancer	durvalumab + tremelimumab Sensitive: B - Late Trials durvalumab + tremelimumab Sensitive : B	durvalumab + tremelimumab Sensitive: B - Late Trials durvalumab + tremelimumab Sensitive : B
BRCA1 mutation	Ovarian Cancer	BRCA1 mutation	Ovarian Cancer	olaparib + tremelimumab Sensitive: C2 – Inclusion Criteria olaparib + tremelimumab Sensitive : C2	olaparib + tremelimumab Sensitive: C2 – Inclusion Criteria olaparib + tremelimumab Sensitive : C2
BRCA2 mutation	Ovarian Cancer	BRCA2 mutation	Ovarian Cancer	olaparib + tremelimumab Sensitive: C2 – Inclusion Criteria olaparib + tremelimumab Sensitive : C2	olaparib + tremelimumab Sensitive: C2 – Inclusion Criteria olaparib + tremelimumab Sensitive : C2
PD-L1 expression	Squamous Cell Carcinoma of Head and Neck	PD-L1 expression	Squamous Cell Carcinoma of Head and Neck	durvalumab + tremelimumab Sensitive: C2 – Inclusion Criteria durvalumab + tremelimumab Sensitive : C2	durvalumab + tremelimumab Sensitive: C2 – Inclusion Criteria durvalumab + tremelimumab Sensitive : C2
MLH1 mutation	Gastric Cancer	MLH1 mutation	Gastric Cancer	tremelimumab Sensitive: C2 – Inclusion Criteria tremelimumab Sensitive : C2	tremelimumab Sensitive: C2 – Inclusion Criteria tremelimumab Sensitive : C2
MLH3 mutation	Gastric Cancer	MLH3 mutation	Gastric Cancer	tremelimumab Sensitive: C2 – Inclusion Criteria tremelimumab Sensitive : C2	tremelimumab Sensitive: C2 – Inclusion Criteria tremelimumab Sensitive : C2

Imjudo (tremelimumab)

Associations
(60)

Associations
(60)

Imjudo (tremelimumab)

Associations(60)

Associations(60)

Associations
(60)

Associations
(60)